Ophthalmic Equipment Market to Witness Steady Growth in the Near Future

The rapid growth in the geriatric population, rising prevalence of eye diseases, and technological advancements in ophthalmic devices are the major factors driving the growth of this market.

The Ophthalmic Equipment Market  size is projected to reach USD 63.3 billion by 2025 from USD 52.8 billion in 2020, at a CAGR of 3.7% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155637364

Market Segmentation:-

Based on product, the ophthalmic equipment market is categorized mainly into diagnostic & monitoring devices, surgical devices, and vision care products. In 2019, the vision care products segment was expected to account for the largest share of the ophthalmology devices market. The large share of this segment can primarily be attributed to the high prevalence of eye disorders such as myopia, hyperopia, astigmatism, and presbyopia. In addition to this, technological advancements in lens materials, growing awareness about eyesight correction, and rising trends in eyewear, such as styled sunglasses and advanced contact lenses boasting extra comfort, have further stimulated the adoption of vision care products.

Recent Developments

• In May 2020, Bausch + Lomb Launched its first EDOF IOL LuxSmart and a monofocal IOL LuxGood with preloaded delivery system and pure refractive optics (PRO) technology.
• In April 2020, Haag-Streit Group (Switzerland) acquired VRmagic Holding AG (Germany) to strengthen Haag-Streit’s leading position in the ophthalmology market
• In February 2020, Bausch + Lomb (Canada)collaborated with Prevent Blindness (US) o raise awareness about AMD through social media pages to share information about AMD with the public.
• In September 2019, Johnson & Johnson Vision Care (US) launched ACUVUE VITA contact lenses for astigmatism in the US
• In February 2019, Carl Zeiss Meditec (Germany)collaborated with Christoffel Mission for the Blind (CBM) (Germany)to open a training center in Pune, India in collaboration with the Poona Blind Men Association

End User:-

Based on end-user, the ophthalmology devices marketis segmented into consumers, hospitals, specialty clinics & ambulatory surgery centers (ASCs), and other end users. specialty clinics & ambulatory surgery centers (ASCs) are expected to grow at the highest CAGR during the forecast period.

Regional Analysis:-

North America is expected to account for the largest share of the ophthalmology devices market in 2019, followed by Europe. In addition, factor such as the growing awareness and uptake of ophthalmic treatments and surgeries and the availability of advanced ophthalmic devices in this region are also driving the growth of the ophthalmic equipment market in North America.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=155637364

Top Key Players:-

The prominent players in this market are EssilorLuxottica (France), Alcon (US), Johnson & Johnson Vision Care (US), HOYA Corporation (Japan), Bausch + Lomb (US), Carl Zeiss Meditec (Germany), Topcon (Japan), Glaukos Corporation (US), Haag-Streit (Switzerland), NIDEK (Japan), STAAR Surgical (US), Ziemer Ophthalmic Systems (Switzerland), CooperVision, Inc. (US), Oculentis (Germany), Heidelberg Engineering (Germany), Canon (Japan), Optovue (US), Neo Vision (Korea), Lumenis (Israel), Reichert Technologies (US), OPHTEC BV (Netherlands), Heine Optotechnik (Germany), and Luneau Technology (France).

Cell Analysis Market: Emerging Trends and Developments

 

Increasing government funding for cell-based research and the rising incidence of chronic and infectious diseases are the major factors driving the growth of this market.

The report Cell Analysis Market is expected to reach USD 22.7 billion by 2024 from USD 16.0 billion in 2019, at a CAGR of 7.2%. from 2019 to 2024.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946

Market Segmentation:-

Based on product, the cell identifications Market is broadly categorized into microscopes, flow cytometry products, spectrophotometers, qPCR products, cell counters, cell microarrays, high-content screening (HCS) systems, and other products. The flow cytometry products segment accounted for the largest market share in 2018. The large share of this segment is primarily attributed to technological advancements, the increasing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the field of immunology and immuno-oncology research, and the rising incidence and prevalence of chronic diseases.

Based on end user, the cell identifications Market is segmented into hospitals & diagnostic laboratories, research institutes, pharmaceutical & biotechnology companies and CROs, cell culture collection repositories, and other end users. The pharmaceutical & biotechnology companies and CROs segment is expected to register the highest CAGR during the forecast period.

Recent Developments:-

• In 2018, Danaher Corporation launched its Kaluza C Flow Cytometry Analysis Software.
• In 2018, Leica Microsystems opened the first Imaging Center in San Francisco. This center will display the breadth of technologies in microscopes, developed by Leica Microsystems for life sciences research.
• In 2018, Becton, Dickinson and Company (BD) launched its BD FACSymphony S6 cell sorter.

Regional Analysis:-

By region, the cell analysis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest market share, followed by Europe.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=157543946

 

Top Key Players:-

The prominent players operating in the cell analysis market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), GE Healthcare (US), Agilent Technologies, Inc. (US), Olympus Corporation (Japan), PerkinElmer, Inc. (US), Promega Corporation (US), Tecan Group (Switzerland), Miltenyi Biotec (Germany), Carl Zeiss (Germany), Bio-Rad Laboratories Inc (US), and Sysmex Corporation (Japan).

Needles Market to Witness Steady Growth in the Near Future

Key factors such growing geriatric population, increasing number of hospitals in emerging markets, and high prevalence of chronic diseases are the major factors driving the growth of the needles market across the globe.

The

Needles Market is expected to reach USD 8.47 Billion by 2022, at CAGR of 7.8% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223979930

Market Segmentation:-              

On the basis of type, the global needles market is segmented into two broad categories, namely, conventional needles and safety needles. The conventional needles market is estimated to command the larger share of the global needles market in 2017. The growing demand for biosimilar products, the increasing incidence of chronic disease, and the expanding injectables market are the key factors contributing to the growth of this market segment.

Based on product, the market is segmented into suture needles, blood collection needles, ophthalmic needles, dental needles, insufflation needles, pen needles, and other needles.

The needles market is segmented into hypodermic, intravenous, intramuscular, and intraperitoneal needles on the basis of delivery mode. The hypodermic needles segment is expected to account for the largest share of the needles market in 2017.

Key Market Drivers: -
            1 High Prevalence of Chronic Diseases
            2 Growing Geriatric Population
            3 Increasing Number of Hospitals in Emerging Markets
            4 Increasing Demand for Vaccines

Regional Analysis:-

As of 2016, North America held the largest share of the global needles market, followed by Europe. Its dominant share is attributed to the rising incidence of chronic diseases, initiatives by different organizations for the reduction in blood borne infections, and increasing prevalence of cardiovascular diseases.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=223979930

Top Key Players:-

The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.).

 

Preimplantation Genetic Testing Market to Progress at a Healthy CAGR in Coming Years

 Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.

The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

Market Segmentation:-

By type, the preimplantation genetic screening segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.

Major Market Drivers :-
            1 Declining Fertility Rates Worldwide
            2 Increasing Public-Private Investments in the Field of Preimplantation Genetic Testing
            3 Rising Number of Fertility Clinics Worldwide
            4 Technological Advancements in the Field of Genetic Analysis
            5 High Risk of Chromosomal Abnormalities With Advancing Maternal Age

Regional Analysis:-

Geographically, the Preimplantation Genetic Diagnosis Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=605

Top Key players:-

As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.

Lithotripsy Devices Market outlook with industry review and forecasts

Factors such as the growing incidence of urolithiasis and technological advancements in lithotripsy devices are driving the growth of this market.

The report Lithotripsy Devices Market  is expected to reach USD 1.76 Billion by 2023 from USD 1.41 Billion in 2018, at a CAGR of 4.5%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=29769904

Market Segmentation:-              

By type, the lithotripsy devices market is classified into extracorporeal shock wave lithotripsy devices and intracorporeal lithotripsy devices. In 2017, the extracorporeal shock wave lithotripsy devices segment accounted for the largest share of the market. ESWL is the least invasive of all stone treatments and is considered the treatment modality of choice for a majority of urinary stones.

On the basis of applications, the lithotripsy devices market is categorized into kidney stones, ureteral stones, pancreatic stones, and bile duct stones. In 2017, the kidney stones segment accounted for the largest share of the market. The increasing incidence of kidney stones and the recurrence of these stones over a period of time are the key factors driving the growth of this segment.

On the basis of end user, the lithotripsy devices market is categorized into hospitals, ambulatory surgical centers, and other end users. In 2017, the hospitals segment accounted for the largest share of the global lithotripsy devices market.

Target Audience for this Report:-

• Manufacturers and vendors of lithotripsy devices
• Research associations related to surgeries
• Various research and consulting firms
• Distributors of lithotripsy devices
• Government bodies
• Venture capitalists

Regional Analysis:-

Based on region, the lithotripsy devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America dominated the lithotripsy devices market in 2017. The large share can primarily be attributed to the high prevalence of kidney stones and the large number of surgeries performed each year.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=29769904

Top key Players:-

Some of the major players in the lithotripsy devices market are Siemens AG (Germany), Boston Scientific (US), Dornier MedTech (Germany), Olympus America (Japan), DirexGroup (Germany), and Richard Wolf (Germany).

 

Genomics Market to Progress at a Healthy CAGR in Coming Years

Factors such as the rising government funding and growth in the number of genomics projects, decreasing sequencing costs, growing application areas of genomics, and the entry of new players and start-ups in the genomics field are driving the growth of the genomics market during the forecast period.

The report Genomics Market  is projected to reach USD 35.7 billion by 2024 from USD 18.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613

Market Segmentation:-                                     

Based on product & service, the Genome Sequencing Market is segmented into consumables, systems & software, and services. In 2018, the consumables segment accounted for the largest share of this market majorly due to the repeated use of consumables for genomic experiments and the increasing number of research programs by academic institutes and non-profit organizations.

By technology, the Genome Sequencing Market is segmented into sequencing, microarray, PCR (polymerase chain reaction), nucleic acid extraction and purification, and other technologies (such as branched DNA analysis, single-cell genomic analysis, and flow cytometry).

Based on application, the Genome Microarray Market is segmented into diagnostics, drug discovery and development, personalized medicine, agriculture and animal research, and other applications (such as forensics and biofuel research).

Market Drivers: -
            1 Rising Government Funding and Growth in the Number of Genomics Projects
            2 Decreasing Sequencing Costs
            3 Growing Application Areas of Genomics
            4 Entry of New Players and Start-Ups in the Genome Microarray Market

Regional Analysis:-

In 2018, North America was the largest regional market for genomics. The large share of North America in the global genomics market can be attributed to the increasing research funding and government initiatives for promoting precision medicine and the use of GM crops in the US. The Asia Pacific market, on the other hand, is expected to register the highest CAGR during the forecast period.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=613

Top key Players:-

Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), BGI (China), GE Healthcare (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Oxford Nanopore Technologies (UK) are the key players operating in the genomics market.

 

Clinical Workflow Solutions Market: Trends and Developments

Growth in this market is driven by the implementation of government initiatives supporting the adoption of HCIT solutions, advantages of clinical workflow solutions in enhancing patient care and safety, increasing patient volume due to the COVID-19 pandemic, growing adoption of EHRs and other HCIT solutions, and the rising need to curtail healthcare costs.

The Clinical Workflow Solutions Market  is projected to reach USD 18.1 billion by 2025 from USD 9.1 billion in 2020, at a CAGR of 14.8% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146901412

Market Segmentation:-

Based on products, the clinical workflow solutions market is segmented into workflow automation solutions, care collaboration solutions, real-time communication solutions, data integration solutions, and enterprise reporting and analytics solutions. The data integration segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the the increasing demand for using medical records and integrating them across hospital departments has been one of the major drivers for data integration solutions.

Based on end users, the clinical workflow solutions market is segmented into hospitals, long-term care facilities, and ambulatory care facilities. The hospital segment is estimated to account for the largest market share in 2019.

Market Drivers:
1 Advantages of clinical workflow solutions in enhancing patient care and safety
2 Government initiatives for HCIT adoption
3 Growing adoption of EHRs and other HCIT solutions
4 Increasing patient volume due to the rising prevalence of chronic diseases and COVID-19
5 Rising need to curtail healthcare costs

Regional Analysis:-

North America is expected to account for the largest share of the clinical workflow solutions market in 2019, followed by Europe. The dominance of the North American region can be attributed to the growing healthcare IT spending, developed infrastructure, evolving regulations for better healthcare outcomes, and the presence of major market players in the region.

Speak To Analyst: – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=146901412

Top Key Players:-

The prominent players in the clinical workflow solutions market are are Hill-Rom Holdings, Inc. (US), Ascom Holding AG (Switzerland), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Cisco Systems, Inc. (US), Stanley Black & Decker, Inc. (US), Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), and McKesson Corporation (US).

 

High Throughput Screening Market to Witness Steady Growth in the Near Future

The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.

The High Throughput Screening Market is expected to reach USD 29.29 billion by 2027 from an estimated USD 14.95 billion in 2019, at a CAGR of 7.8%.

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

Market Segmentation: -

On the basis of product and service, the reagents & assay kits segment accounted for the largest share of the global HTS market. The large share of this segment can be attributed to factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research.

Based on technology, the High Throughput Screening Industry is segmented into cell-based assays, lab-on-a-chip (LOC), ultra-high-throughput screening (uHTS), label-free technology, and bioinformatics. In 2018, the cell-based assays segment accounted for the largest share of the HTS market.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the High Throughput Screening Industry.

Key Market Drivers: –
1 Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies
2 Government Funding and Venture Capital Investments
3 Increasing R&D Spending
4 Technological Advancements

Regional Analysis: -

North America accounted for the largest share of the HTS market in 2018, followed by Europe and Asia Pacific.

Speak to Analyst:  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=134981950

Top key Players: -

The prominent players in the global HTS market are Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton (US), Corning (US), BioTek (US), and Aurora Biomed (Canada).

Hematology Analyzers and Reagents Market: Trends and Developments

The increasing incidence of blood disorders and the growth in the number of blood donation are the major factors driving the growth of the global hematology analyzers and reagents market. Technological advancements in hematology analyzers and reagents and the integration of flow cytometry techniques with hematology analyzers are also expected to support the growth of this market during the forecast period.

The report Hematology Analyzers and Reagents Market  is projected to reach USD 10.6 billion by 2025 from USD 7.6 billion in 2020, at a CAGR of 6.9% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153222146

Market Segmentation:-

On the basis of products & services, the hematology reagents market is classified into hematology, hemostasis, and immunohematology products & services. The hematology products & services segment is projected to grow at the highest growth rate during the forecast period.

By end user, the hematology analyzers market is segmented into hospital laboratories, commercial service providers, government reference laboratories, and research & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the market due to factors such as the increasing awareness about hematology testing, shift from manual testing to automated testing, and the competitive benefits offered by these providers as compared to hospitals (such as affordable service costs, efficient turnaround time, and efficient management of sample collection).

Recent Developments:-

• In February 2018, Sysmex entered into an agreement with McKesson to distribute Sysmex’s XW-100 automated hematology analyzers in the US.
• In September 2017, Sysmex entered into an agreement with Mongolia’s Ministry of Health to provide technological, scientific, and external quality assessment support in the field of blood morphology to raise the accuracy of testing in the Mongolian region.
• Sysmex expanded its direct sales network in the Republic of Ghana (Africa) to reinforce its hematology sales and service structure in the African market.
• In July 2017, Sysmex launched XN-9100, XN-3100, XN-1500, and SP-50 (an automated hematology slide preparation unit).
• In July 2017, Sysmex launched the XN-L automated hematology analyzers in the US.

 

Regional Analysis:-

North America accounted for the largest share of the market in 2019. This can be attributed to the rising incidence of patients suffering from blood disorders, the growing prevalence of target diseases, and the rising demand for blood transfusions in the region.

Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153222146

Top key Players:-

The major players in the global hematology reagents market are Sysmex Corporation (Japan), Abbott Laboratories (US), Danaher Corporation (US), Nihon Kohden (Japan), Siemens (Germany), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (US), EKF Diagnostics (UK), Mindray (China), Ortho Clinical Diagnostics (US), and Roche (Switzerland).

Stem Cell Therapy Market: Trends and Developments

Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.

The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

Market Segmentation:-

On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period.

On the basis of therapeutic application, the global Stem Cell Therapy Industry is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period.

On the basis of cell source, the global Stem Cell Therapy Industry is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017.

Market Growth Drivers :-
            1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management
            2 Development of Advanced Genome-Based Cell Analysis Techniques
            3 Increasing Public-Private Investments for the Development of Stem Cell Therapies
            4 Development in Infrastructure Related to Stem Cell Banking and Processing

Regional Analysis:-

North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=48

Key Market Players:-

As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market.